Alnylam Pharmaceuticals (ALNY) Earns Outperform Rating from Analysts at Evercore ISI

Equities researchers at Evercore ISI initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report released on Thursday, The Fly reports. The firm set an “outperform” rating on the biopharmaceutical company’s stock.

ALNY has been the subject of several other reports. ValuEngine cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 2nd. Piper Jaffray Companies lowered their target price on Alnylam Pharmaceuticals to $152.00 and set an “overweight” rating for the company in a research note on Tuesday, January 15th. BidaskClub raised Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, January 10th. Zacks Investment Research raised Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, January 17th. Finally, Cowen reissued a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 6th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and sixteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $128.35.

Shares of NASDAQ ALNY traded down $2.79 during midday trading on Thursday, hitting $88.10. The stock had a trading volume of 790,618 shares, compared to its average volume of 802,073. The stock has a market capitalization of $9.66 billion, a P/E ratio of -11.64 and a beta of 2.61. Alnylam Pharmaceuticals has a fifty-two week low of $60.27 and a fifty-two week high of $124.21. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.56 and a current ratio of 6.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 7th. The biopharmaceutical company reported ($2.09) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.27) by $0.18. The company had revenue of $21.00 million during the quarter, compared to analysts’ expectations of $18.03 million. Alnylam Pharmaceuticals had a negative return on equity of 50.82% and a negative net margin of 1,016.58%. The business’s revenue for the quarter was down 44.6% on a year-over-year basis. During the same period last year, the firm earned ($1.20) EPS. Equities research analysts forecast that Alnylam Pharmaceuticals will post -9.02 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the stock. FUKOKU MUTUAL LIFE INSURANCE Co grew its stake in shares of Alnylam Pharmaceuticals by 40.0% during the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 700 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 200 shares during the period. Resources Investment Advisors Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $58,000. Huntington National Bank acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $73,000. ETF Managers Group LLC grew its stake in shares of Alnylam Pharmaceuticals by 15.7% during the fourth quarter. ETF Managers Group LLC now owns 1,086 shares of the biopharmaceutical company’s stock worth $79,000 after purchasing an additional 147 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in shares of Alnylam Pharmaceuticals by 768.5% during the third quarter. Tower Research Capital LLC TRC now owns 1,294 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,145 shares during the period. 86.88% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Featured Article: What is Cost of Debt?

The Fly

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.